$VYGR
Voyager Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000155837020005300 Filed on May 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $18.07M $5.197M
YoY Change 247.64% 451.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.20M $9.700M
YoY Change 5.15% 34.72%
% of Gross Profit
Research & Development $32.29M $24.83M
YoY Change 30.06% 66.65%
% of Gross Profit
Depreciation & Amortization $842.0K $616.0K
YoY Change 36.69% 23.2%
% of Gross Profit
Operating Expenses $42.50M $34.49M
YoY Change 23.22% 56.52%
Operating Profit -$24.43M -$29.29M
YoY Change -16.59% 38.88%
Interest Expense $978.0K $1.145M
YoY Change -14.59% 90.83%
% of Operating Profit
Other Income/Expense, Net $170.0K $2.123M
YoY Change -91.99% 430.75%
Pretax Income -$24.30M -$27.20M
YoY Change -10.66% 35.32%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.26M -$27.17M
YoY Change -10.7% 36.35%
Net Earnings / Revenue -134.29% -522.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$656.8K -$814.4K
COMMON SHARES
Basic Shares Outstanding 37.15M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $250.9M $358.5M
YoY Change -30.01% 64.3%
Cash & Equivalents $165.2M $113.3M
Short-Term Investments $85.70M $245.2M
Other Short-Term Assets $5.300M $6.700M
YoY Change -20.9% 179.17%
Inventory
Prepaid Expenses
Receivables $16.30M
Other Receivables $0.00
Total Short-Term Assets $272.5M $365.2M
YoY Change -25.39% 65.55%
LONG-TERM ASSETS
Property, Plant & Equipment $18.59M $43.40M
YoY Change -57.18% 277.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.400M $1.300M
YoY Change 7.69% 0.0%
Other Assets $2.400M $1.500M
YoY Change 60.0% -6.25%
Total Long-Term Assets $50.13M $46.10M
YoY Change 8.75% 220.14%
TOTAL ASSETS
Total Short-Term Assets $272.5M $365.2M
Total Long-Term Assets $50.13M $46.10M
Total Assets $322.6M $411.3M
YoY Change -21.56% 75.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.815M $2.300M
YoY Change 109.35% 64.29%
Accrued Expenses $17.49M $9.300M
YoY Change 88.1% -1.06%
Deferred Revenue $46.92M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.54M $58.80M
YoY Change 23.36% 90.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.09M $31.98M
YoY Change -2.77% -69.78%
Total Long-Term Liabilities $31.09M $31.98M
YoY Change -2.77% -69.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.54M $58.80M
Total Long-Term Liabilities $31.09M $31.98M
Total Liabilities $242.9M $310.7M
YoY Change -21.84% 127.29%
SHAREHOLDERS EQUITY
Retained Earnings -$336.9M
YoY Change
Common Stock $37.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.76M $100.7M
YoY Change
Total Liabilities & Shareholders Equity $322.6M $411.3M
YoY Change -21.56% 75.02%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$24.26M -$27.17M
YoY Change -10.7% 36.35%
Depreciation, Depletion And Amortization $842.0K $616.0K
YoY Change 36.69% 23.2%
Cash From Operating Activities -$28.80M $125.2M
YoY Change -123.01% 157.53%
INVESTING ACTIVITIES
Capital Expenditures $1.507M $1.104M
YoY Change 36.5% -169.0%
Acquisitions
YoY Change
Other Investing Activities $110.5M -$135.6M
YoY Change -181.49% -326.0%
Cash From Investing Activities $109.0M -$136.7M
YoY Change -179.75% -334.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.00K 77.90M
YoY Change -99.96% 4227.83%
NET CHANGE
Cash From Operating Activities -28.80M 125.2M
Cash From Investing Activities 109.0M -136.7M
Cash From Financing Activities 34.00K 77.90M
Net Change In Cash 80.23M 66.40M
YoY Change 20.82% -38.97%
FREE CASH FLOW
Cash From Operating Activities -$28.80M $125.2M
Capital Expenditures $1.507M $1.104M
Free Cash Flow -$30.31M $124.1M
YoY Change -124.43% 147.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36976751
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36865116
CY2020Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2019Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherCurrentLiabilitiesMember
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentLiabilitiesMember
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-37625
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
75 Sidney Street
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020Q1 dei City Area Code
CityAreaCode
857
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020Q1 dei Trading Symbol
TradingSymbol
VYGR
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37190692
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165227000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86042000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
85704000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
195491000
CY2020Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
16283000
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18496000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5262000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4630000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
272476000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
304659000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18586000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17986000
CY2020Q1 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2378000
CY2019Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1723000
CY2020Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1432000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1920000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27738000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28472000
CY2020Q1 us-gaap Assets
Assets
322610000
CY2019Q4 us-gaap Assets
Assets
354760000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4815000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4070000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17493000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21516000
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3306000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3193000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
46923000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
47233000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
72537000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
76012000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
139227000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
147260000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31089000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31976000
CY2020Q1 us-gaap Liabilities
Liabilities
242853000
CY2019Q4 us-gaap Liabilities
Liabilities
255248000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36976751
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36865116
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
37000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
416210000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
412227000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
421000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336911000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-312648000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
79757000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
322610000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354760000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18067000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5197000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32294000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24831000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10206000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9659000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
42500000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
34490000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24433000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
745000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-29293000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
978000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1145000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-808000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
978000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
170000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2123000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24263000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27170000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
525000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
525000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
58000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23738000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27112000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36963255
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33353061
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
46446000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2019Q1 vygr Stock Issued During Period Value Collaboration Agreement
StockIssuedDuringPeriodValueCollaborationAgreement
77617000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3459000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27170000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
100694000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3949000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
525000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24263000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
79757000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-24263000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-27170000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4040000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3518000
CY2020Q1 us-gaap Depreciation
Depreciation
842000
CY2019Q1 us-gaap Depreciation
Depreciation
616000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
188000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
554000
CY2019Q1 vygr In Kind Research And Development Expenses
InKindResearchAndDevelopmentExpenses
392000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-808000
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
965000
CY2020Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-2213000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
CY2020Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-734000
CY2019Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-670000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1223000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4626000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
CY2020Q1 vygr Proceeds From Issuance Of Equity And Collaboration Agreements
ProceedsFromIssuanceOfEquityAndCollaborationAgreements
640000000.0
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-580000
CY2020Q1 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-774000
CY2019Q1 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-606000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8343000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
148611000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28798000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
125162000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1507000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104000
CY2019Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
122000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
214979000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
110500000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
79300000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
108993000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136661000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
284000
CY2019Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
77617000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77901000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80229000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
66402000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47594000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167006000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113996000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
65000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">NOTE</b><b style="font-weight:bold;">S TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">Voyager Therapeutics, Inc. (the “Company”) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. The Company is focused on neurological diseases where it believes an adeno-associated virus (“AAV”) gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The Company has built a gene therapy platform that it believes positions itself to be a leading company at the intersection of AAV gene therapy and severe neurological disease. The Company’s gene therapy platform enables it to engineer, optimize, manufacture and deliver its AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">Additionally, the Company is working to identify novel AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload. The Company’s team of experts in the fields of AAV gene therapy and neuroscience first identifies and selects severe neurological diseases that are well-suited for treatment using AAV gene therapy. The Company then engineers and optimizes AAV vectors for delivery of the virus payload to the targeted tissue or cells. The Company’s manufacturing process employs an established system that it believes will enable production of high quality AAV vectors at commercial-scale. I</span>n addition to the Company’s capsid optimization efforts, it leverages novel delivery paradigms, established routes of administration, and advances in dosing techniques to optimize delivery of its AAV gene therapies to target tissues, regions and cell types that are critical to the disease of interest. The Company believes it can achieve this directly, with targeted infusions to discrete regions of the brain, the spinal cord, or systemically, in conjunction with its novel capsids.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy development and manufacturing and is beginning to build its commercial infrastructure. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in certain geographies with collaborators, as the Company has demonstrated through its <span style="background-color:#ffffff;">collaboration with </span>Sanofi Genzyme Corporation<span style="background-color:#ffffff;"> (the “</span>Sanofi Genzyme<span style="background-color:#ffffff;"> Collaboration”), its collaboration with </span>AbbVie Biotechnology Ltd (the “<span style="background-color:#ffffff;">AbbVie Tau Collaboration”), its collaboration with Neurocrine Biosciences, Inc. (the “Neurocrine Collaboration”), and its collaboration with AbbVie Ireland Unlimited Company (the “AbbVie Alpha-Synuclein Collaboration”)</span>. The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred annual net operating losses in every year since inception. As of March 31, 2020, the Company had an accumulated deficit of $336.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from its collaborations with <span style="font-family:'Times';">Sanofi Genzyme Corporation (“Sanofi Genzyme”), AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and Neurocrine Biosciences, Inc. (“Neurocrine”)</span>. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Through March 31, 2020, the Company has raised approximately $640.0 million of proceeds from sales of convertible preferred stock and common stock, including its initial public offering and follow-on public offering, and proceeds from collaboration agreements. <span style="background-color:#ffffff;">As of March 31, 2020, the Company had cash, cash equivalents, and marketable debt securities</span> of $250.9 million. <span style="background-color:#ffffff;">Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable debt securities, as well as ongoing reimbursement amounts expected </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">from development costs related to its collaboration and license agreement with Neurocrine, or the Neurocrine Collaboration Agreement, will enable the Company to meet its planned operating expenses and capital expenditure requirements into mid-2022</span><span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenue from collaboration partners on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</p>
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336900000
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
250900000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 6pt 0pt;"><i style="font-family:'Times New Roman';font-style:italic;">Use of estimates</i></p><p style="font-family:'Calibri';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman';">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</span></p>
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86374000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
762000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
87136000
CY2020Q1 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
239769000
CY2020Q1 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
762000
CY2020Q1 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
240531000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
196687000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
752000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
197411000
CY2019Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
274990000
CY2019Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
752000
CY2019Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
28000
CY2019Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
275714000
CY2020Q1 vygr Debt Securities Contractual Maturity Period
DebtSecuritiesContractualMaturityPeriod
P1Y
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165227000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113261000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
1779000
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
735000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167006000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113996000
CY2020Q1 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
10082000
CY2019Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
13248000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4222000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5733000
CY2020Q1 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1637000
CY2019Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1386000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1347000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
897000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
130000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
177000
CY2020Q1 vygr Accrued Patent Costs Current
AccruedPatentCostsCurrent
75000
CY2019Q4 vygr Accrued Patent Costs Current
AccruedPatentCostsCurrent
75000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17493000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21516000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6323000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6512000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
6707000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
14190000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
44340000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10946000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
33394000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3306000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30088000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
33394000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4470000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6138000
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2020Q1 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
8.5
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3306000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3193000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
15.66
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3518000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6065155
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3306000
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3193000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30088000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30975000
CY2020Q1 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2019Q1 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31089000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31976000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4040000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4040000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3518000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5317326
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.98
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
899085
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.88
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3035
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.30
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
148221
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.53
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
391000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2723252
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.77
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
350000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6065155
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.53
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
391000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6989053
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5430003

Files In Submission

Name View Source Status
0001558370-20-005300-index-headers.html Edgar Link pending
0001558370-20-005300-index.html Edgar Link pending
0001558370-20-005300.txt Edgar Link pending
0001558370-20-005300-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20200331xex31d1.htm Edgar Link pending
vygr-20200331xex31d2.htm Edgar Link pending
vygr-20200331xex32d1.htm Edgar Link pending
vygr-20200506.xsd Edgar Link pending
vygr-20200506x10q.htm Edgar Link pending
vygr-20200506x10q006.jpg Edgar Link pending
vygr-20200506x10q_htm.xml Edgar Link completed
vygr-20200506_cal.xml Edgar Link unprocessable
vygr-20200506_def.xml Edgar Link unprocessable
vygr-20200506_lab.xml Edgar Link unprocessable
vygr-20200506_pre.xml Edgar Link unprocessable